StockData
Heron Therapeutics, Inc. logo

Heron Therapeutics, Inc. (HRTX) stock

HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/30
$0.28−0.00 (-0.74%)

Close on Nov 17, 2026Market cap $53.58MP/E –Yield –

Heron Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Heron Therapeutics's enterprise value was $23.64M on Nov 11, 2026, against $140.09M a year earlier. Over the last 5 years it ranged from $8.58M to $1.39B, with a median of $199.88M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$23.64M-85.6%
2025Dec 31, 2025$163.69M+1.3%
2024Dec 31, 2024$161.52M+18.4%
2023Dec 29, 2023$136.41M-55.0%
2022Apr 29, 2022$303.46M-54.8%
2021Dec 31, 2021$671.02M-59.4%
2020Dec 31, 2020$1.65B+3.3%
2019Dec 31, 2019$1.60B+14.3%
2018Dec 31, 2018$1.40B+70.5%
2017Dec 29, 2017$820.99M+106.7%
2016Dec 30, 2016$397.25M-41.9%
2015Dec 31, 2015$684.32M+343.0%
2014Dec 31, 2014$154.46M+34.6%
2013Dec 31, 2013$114.76M+73.8%
2012Apr 30, 2012$66.05M+435.1%
2011Jul 29, 2011$12.34M–

More Heron Therapeutics figures

See a number that looks wrong?